Dungubat, Erdenetsogt
Loading...
Товч нэр
Dungubat, Erdenetsogt
Бүтэн нэр
Dungubat Erdenetsogt
Латин нэр
Dungubat Erdenetsogt
Албан тушаал
Судлаач
11 results
Now showing 1 - 10 of 11
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Impact of Hepatitis D Coinfection on the Hepatitis Flare during Chemotherapy for B-Cell Non-Hodgkin Lymphoma(Mongolian National University of Medical Sciences, 2020-04-01); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Hepatitis C Associated B-Cell Non-Hodgkin Lymphoma: Impact of Combination Direct-Acting Antivirals and Chemotherapy(Mongolian National University of Medical Sciences, 2021-12-31); ; Objectives: Direct-acting antiviral agents (DAAs) have successfully eradicated chronic hepatitis C virus (HCV) infection. Since chronic HCV is known to have an increased risk of developing B cell non-Hodgkin lymphoma (B-NHL), successful HCV treatment may have virologic, hepatic, and oncologic benefits for B-NHL. Therefore, this study aimed to determine the efficacy of DAAs combined with chemotherapy in B-NHL patients with chronic HCV in Mongolia. Methods: This case-control study included newly diagnosed B-NHL patients with chronic HCV who received DAAs before chemotherapy (with DAAs group). The other is comprised of controls who have been treated by chemotherapy without DAAs. Patients who received courses of DAAs were monitored by the virological and hepatic responses. Results: Eleven patients received DAAs and none of them developed chemotherapy-associated hepatitis flare. Of the DAAs group, during DAAs treatment, 90.9% were clinically stable. In all cases of DAAs in combination with chemotherapy, the Sustained Viral Response (SVR)12 and 24 were 100%. However, 47.4% of those who received DAAs after chemotherapy developed hepatitis flare during chemotherapy. Patients with hepatitis flare had higher serum level of ALT before chemotherapy (15.7 U/L vs. 40.2 U/L; p = 0.014) than those without. Conclusion: DAAs administration results in a significant clinical benefit to B-NHL patients with chronic HCV. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Helicobacter pylori-ийн халдварын дахилт, түүнд нөлөөлөх зарим эрсдэлт хүчин зүйлс(2021-09-01); ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, В эсийн Ходжкины бус лимфома оношлогдсон эмчлүүлэгчдэд вирүсийн эсрэг эмчилгээний зарим үр дүн(2021-03-21); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.(2023-10); Scopus© Citations 54 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Age-dependent sex difference of non-alcoholic fatty liver disease in TSOD and db/db mice.(2022); Scopus© Citations 14 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, 2015-2019 онд Монгол насанд хүрэгчдийн дунд оношлогдсон лимфом, В-эсийн Ходжкины бус лимфомын тохиолдлууд(2022-04-28); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Effects of Caffeine and Chlorogenic Acid on Nonalcoholic Steatohepatitis in Mice Induced by Choline-Deficient, L-Amino Acid-Defined, High-Fat Diet.(2020-12); Scopus© Citations 22 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Artificial intelligence and deep learning: New tools for histopathological diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.(2023); Scopus© Citations 33 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Effects of low ethanol consumption on nonalcoholic steatohepatitis in mice.(2020-09)Scopus© Citations 4